74P – Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world
Real-world economic value of a 21-gene assay in early-stage breast cancer
Growth factor use and costs in breast cancer patients undergoing adjuvant therapy
Early economic benefits of gene expression profiling using a 21-gene panel among patients with early stage, lymph node negative, hormone receptor positive, her2-neu oncogene negative breast cancer
Characterization of early stage Breast Cancer patient management in a practice setting with the 21-Gene Breast Cancer assay
